Results 121 to 130 of about 4,368 (233)

Pituitary gigantism: a case series from Hospital de San José (Bogotá, Colombia)

Archives of Endocrinology and Metabolism
Introduction Gigantism is a rare pediatric disease characterized by increased production of growth hormone (GH) before epiphyseal closure, that manifests clinically as tall stature, musculoskeletal abnormalities, and multiple comorbidities.
William Rojas García, Henry Tovar Cortes, Andrés Florez Romero   +2 more
doaj   +1 more source

Pegvisomant-Induced Cholestatic Hepatitis in an Acromegalic Patient with UGT1A1 ​⁎ 28 Mutation

Case Reports in Endocrinology, 2016
Pegvisomant (PEGv) is a growth hormone receptor antagonist approved for the treatment of acromegaly; one of its documented adverse effects is reversible elevation of hepatic enzymes.
Maria Susana Mallea-Gil, Ignacio Bernabeu, Adriana Spiraquis, Alejandra Avangina, Lourdes Loidi, Carolina Ballarino   +5 more
doaj   +1 more source

Growth factor, energy and nutrient sensing signalling pathways in metabolic ageing [PDF]

, 2017
The field of the biology of ageing has received increasing attention from a biomedical point of view over the past decades. The main reason has been the realisation that increases in human population life expectancy are accompanied by late onset diseases.
Bettedi, L, Foukas, LC
core   +1 more source

Efficacy and Safety of switching to Pasireotide in Acromegaly Patients controlled with Pegvisomant and Somatostatin Analogues: PAPE extension study.

European Journal of Endocrinology, 2018
OBJECTIVE to assess the efficacy and safety after 48 weeks of treatment with pasireotide long-acting-release (PAS-LAR) alone or in combination with pegvisomant in patients with acromegaly.
A. Muhammad, Eva C. Coopmans, P. Delhanty, A. Dallenga, Iain K. Haitsma, J. Janssen, A. J. van der Lely, S. Neggers   +7 more
semanticscholar   +1 more source

Patients with Active Acromegaly are at High Risk of 25(OH)D Deficiency [PDF]

, 2015
Acromegaly is a chronic disease characterized by hypersecretion of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Electrolyte disturbances such as hypercalcemia and hyperphosphatemia are reported in patients with this disorder.
Aleksandra Jawiarczyk-PrzybyÅ‚owska, Jowita Halupczok-Å»yÅ‚a, Marek Bolanowski   +2 more
core   +2 more sources

Carbohydrate metabolism in patients with acromegaly and Itsenko—Cushing disease

Терапевтический архив, 2015
The relevance of investigating carbohydrate metabolism (CM) in patients with acromegaly and Itsenko—Cushing disease is attributable to frequent glucose metabolic disturbances, on the one hand, and to difficulties in choosing sugar-lowering therapy in ...
L V Matchekhina, Zh E Belaya, G A Melnichenko, M V Shestakova   +3 more
doaj  

High prevalence of hypovitaminosis D in Sicilian children affected by growth hormone deficiency and its improvement after 12 months of replacement treatment. [PDF]

, 2014
PURPOSE: Although the correlation between vitamin D and growth hormone (GH)-insulin-like growth factor 1 (IGF1) axis is documented, as of date, few and conflicting studies have prospectively analyzed vitamin D before and after GH treatment.
Cicciò, F, CIRESI, Alessandro, GIORDANO, Carla   +2 more
core   +1 more source

How Different Treatments for Acromegaly Modulate Sleep Quality: A Psychometric Study

Endocrines
Acromegaly is a rare endocrine syndrome characterized by unrestrained growth hormone (GH) secretion from a GH-secreting pituitary neuroendocrine tumor (PitNET).
Gaspare Alfì, Danilo Menicucci, Dalì Antonia Ciampa, Vito Di Giura, Giulia Marconcini, Claudio Urbani, Fausto Bogazzi, Angelo Gemignani   +7 more
doaj   +1 more source

Efficacy and Safety of Pegvisomant in the Treatment of Acromegaly.

Archives of Medical Research, 2023
Linus Haberbosch, C. Strasburger
semanticscholar   +1 more source

Surgery, Octreotide, Temozolomide, Bevacizumab, Radiotherapy, and Pegvisomant Treatment of an AIP Mutation‒Positive Child

Journal of Clinical Endocrinology and Metabolism, 2019
Context Inactivating germline mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene are linked to pituitary adenoma predisposition. Here, we present the youngest known patient with AIP-related pituitary adenoma.
P. Dutta, K. S. Reddy, A. Rai, Anil K. Madugundu, Hitendra S Solanki, A. Bhansali, B. Radotra, Narendra Kumar, D. Collier, D. Iacovazzo, Prakamya Gupta, R. Raja, H. Gowda, A. Pandey, J. Devgun, M. Korbonits   +15 more
semanticscholar   +1 more source